1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma. UPDATED 2011. www.ginasthma.org

2. Barnes P.J. Mechanisms in COPD. Differences from asthma. Chest 2000; 117: 10–14.

3. Kanner R.E., Connett J.E., Altose M.D. et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am. J. Respir. Crit. Care Med. 1994; 150 (4): 956–961.

4. Yang S.C., Lin B.Y. Comparison of airway hyperreactivity in chronic obstructive pulmonary disease and asthma. Chang Gung Med. J. 2010; 33: 515–523.

5. Трофименко И.Н., Черняк Б.А. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Пульмонология 2011; 4: 49–53.

6. Brutsche M.H., Downs S.H., Schindler C. et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study. Thorax 2006; 61: 671–677.

7. Xu X., Rijcken B., Schouten J.P. et al. Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Lancet 1997; 350: 1431–1434.

8. De Marco R., Accordini S., Marcon A. et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am. J. Respir. Crit. Care Med. 2011; 183 (7): 891–897.

9. Tashkin D.P., Altose M.D., Connett J.E. et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am. J. Respir. Crit. Care Med. 1996; 153: 1802–1811.

10. Hospers J.J., Postma D.S., Rijcken B. et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313–1317.

11. Grootendorst D.C., Rabe K.F. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004; 1: 77–87.

12. Wise R.A., Kanner R.E., Lindgren P. et al. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest 2003; 124: 449–458.

13. Postma D.S., Kerstjens H.A.M. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 187–192.

14. Lancas T., Kasahara D.I., Gross J.L. et al. Cholinergic hyperresponsiveness of peripheral lung parenchyma in chronic obstructive pulmonary disease. Respiration 2011; 82: 177–184.

15. Fisher J.T., Vincent S.G., Gomeza J. et al. Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J. 2004; 18 (6): 711–713.

16. Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2: 297–304.

17. O'Connor B.J., Towse L.J., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 876–880.

18. Gosens R., Zaagsma J., Meurs H. et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 2006; 7 (1): 73.

19. Cao R., Dong X.W., Jiang J.X. et al. M (3) muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice. Eur. J. Pharmacol. 2011; 655: 83–90.

20. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. www.goldcopd.org

21. Gulsvik A., Refvem O.K. Ascoring system on respiratory symptoms. Eur. Respir. J. 1988; 1: 428–432.

22. Чучалин А.Г. (ред.). Пульмонология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2005. 212–213.

23. Klein G., Köhler D., Bauer C.P. et al. Standartization of inhalation chal-lenges for measuring the unspecific bronchial inhalation challenge by re-servuar-method. Pneumologie 1991; 45: 60–64.

24. Стандартизация легочных функциональных тестов: Пер. с англ. под ред. А.Г.Чучалина. М.; 1993. 68–69.

25. Troosters T., Celli B., Lystig T. et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trial. Eur. Respir. J. 2010; 36 (1): 65–73.

26. Selivanova P.A., Kulikov E.S., Kozina O.V. et al. Differential expression of the β2-adrenoreceptor and M3-cholinoreceptor genes in bronchial mucosa of patients with asthma and chronic obstructive pulmonary disease. Ann. Allergy Asthma Immunol. 2012; 108: 39–43.